| Barreto, Andrew D |
SEGA, NCT03263117: SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke |
|
|
| Completed | 4 | 260 | US | Sedation, General Anesthesia (GA), Intra-arterial Thrombectomy, Endovascular Therapy | The University of Texas Health Science Center, Houston, Stryker Neurovascular | Stroke | 04/23 | 04/23 | | |
| Recruiting | 2 | 300 | US | TS23 | Translational Sciences, Inc., University of Cincinnati, National Institute of Neurological Disorders and Stroke (NINDS), Medical University of South Carolina, University of Arizona | Ischemic Stroke | 07/27 | 12/27 | | |
| McCarthy, James J |
| Completed | 1 | 27 | RoW | UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose, Placebo | Emergent BioSolutions | Human Influenza | 10/23 | 10/23 | | |
HD-MAP, NCT06417853: Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch |
|
|
| Recruiting | 1 | 258 | RoW | Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Injection, Unadjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Injection, Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, low dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (low dose HA, high dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, low dose adjuvant), Adjuvanted Influenza A (H7N9) Monovalent Vaccine Microarray Patch Delivery System (high dose HA, high dose adjuvant), Microarray Patch Delivery System | Vaxxas Pty Ltd, Biomedical Advanced Research and Development Authority | H7N9 Influenza | 05/26 | 05/26 | | |
| Recruiting | N/A | 2000000 | US | Exome sequencing | Helix, Inc, Medical University of South Carolina, HealthPartners Institute, Memorial Hermann Health System, WellSpan Health, St. Luke's Hospital and Health Network, Pennsylvania, Nebraska Medicine - University of Nebraska Medical Center | Genetic Predisposition to Disease, Genetics Disease | 09/31 | 09/36 | | |
| Savitz, Sean I |
SEGA, NCT03263117: SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke |
|
|
| Completed | 4 | 260 | US | Sedation, General Anesthesia (GA), Intra-arterial Thrombectomy, Endovascular Therapy | The University of Texas Health Science Center, Houston, Stryker Neurovascular | Stroke | 04/23 | 04/23 | | |
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis |
|
|
| Recruiting | 3 | 1683 | US | Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management | University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca | Intracranial Arteriosclerosis, Stroke | 05/28 | 05/28 | | |
NCT03915431: A Study of NCS-01 in Patients With Acute Ischemic Stroke |
|
|
| Active, not recruiting | 1/2 | 16 | US | NCS-01 | NC Medial Research Inc | Ischemic Stroke | 10/27 | 10/28 | | |
EMAGINE, NCT05044507: The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "" STUDY) |
|
|
| Completed | N/A | 100 | US | BQ 2.0, BQ 2.0 sham stimulation group, BQ 2.0 active stimulation group | BrainQ Technologies Ltd. | Ischemic Stroke | 11/23 | 01/24 | | |
NS-CIP-001, NCT06288217: Non-invasive Trigeminal and Vagus Nerve Stimulation for Stroke Subjects With Chronic Upper Extremity Deficits |
|
|
| Recruiting | N/A | 25 | US | NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation), nTVNS, Upper Limb Rehabilitation, Sham Stimulation | NeuraStasis, Inc | Stroke, Ischemic, Upper Extremity Paresis | 12/24 | 12/24 | | |
NCT06386874: EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment |
|
|
| Recruiting | N/A | 122 | US | Q Therapeutic System (BQ 3.0) - Sham, BQ 3.0 Sham Stimulation Group, Q Therapeutic System (BQ 3.0) - Active, BQ 3.0 Active Stimulation Group Interventions | BrainQ Technologies Ltd. | Ischemic Stroke | 07/26 | 10/26 | | |
| Garrett, Jennifer |
AQUAX2, NCT05926765: A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US | AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, Placebo | MeiraGTx, LLC | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands | 07/25 | 07/25 | | |
| Recruiting | 1/2 | 40 | US | Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion | The Methodist Hospital Research Institute, Genentech, Inc. | Schizo-Affective Type of Psychosis, Schizophrenia | 06/25 | 10/25 | | |
MyPEAK-1, NCT05836259: Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM |
|
|
| Recruiting | 1/2 | 30 | US | TN-201 | Tenaya Therapeutics | Hypertrophic Cardiomyopathy | 08/27 | 08/32 | | |
| Recruiting | 1 | 140 | Europe, US | SEA-CD70, azacitidine, VIDAZA | Seagen Inc. | Myelodysplastic Syndrome, Acute Myeloid Leukemia | 12/24 | 11/26 | | |
| Recruiting | N/A | 125 | US | smaller incision, new generation implantable miniature telescope (SING-IMT) | VisionCare, Inc., ORA, Inc. | Age-Related Macular Degeneration, Geographic Atrophy | 12/25 | 12/25 | | |
NCT05736848: A Retrospective Assessment of OviTex PRS (OviTex) |
|
|
| Recruiting | N/A | 200 | US | OviTex® PRS, OviTex PRS Permanent - Pre-pectoral, OviTex PRS Permanent - Sub-pectoral, OviTex PRS Resorbable - Pre-pectoral, OviTex PRS Resorbable - Sub-pectoral | Tela Bio Inc, MCRA | Reconstructive Surgical Procedures | 07/25 | 12/25 | | |
